Shell Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Shell Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,153	Closed	-$156K	–	1281
2023 Q1	$156K	Buy	+2,153	New	+$209K	0.01%	1009

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Shell Asset Management's ATRA Position: Q2 2023 in Review

Shell Asset Management sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 2,153 shares — an estimated $156K sold.

Shell Asset Management first reported a position in ATRA in Q1 2023 and held it in 1 quarter. The position peaked at $156K in Q1 2023. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

Shell Asset Management reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
Shell Asset Management sold 2,153 Atara Biotherapeutics shares in Q2 2023, an estimated $156K.
Shell Asset Management first reported a position in Atara Biotherapeutics in Q1 2023 and held it in 1 quarter.
Shell Asset Management's Atara Biotherapeutics position peaked at $156K in Q1 2023.
118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Shell Asset Management's 13F filing for Q2 2023, filed 28 Jul 2023.